Drilldown: Medicines

Flibanserin (1) · Losartan (1) · Phencyclidine (1) · Sitagliptin (1)

Addyi (1) · Cozaar (1) · Januvia; with metformin Janumet/Janumet XR (1) · Sernyl (human, withdrawn 1965); Sernylan (veterinary, withdrawn 1978) (1)

Multimodal serotonergic; HSDD treatment (1) · [[:Category:Anesthetics|Anesthetic (historical)]] (1) · [[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] (1) · [[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (1) · [[:Category:Antihypertensives|Antihypertensive]] (1) · [[:Category:Arylcyclohexylamines|Arylcyclohexylamine]] (1) · [[:Category:Dissociatives|Dissociative]] (1) · [[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (1) · [[:Category:Incretin_modulators|Incretin pathway modulator]] (1) · [[:Category:NMDA_receptor_antagonists|NMDA receptor antagonist]] (1) · [[:Category:Sigma-1_receptor_agonists|Sigma-1 receptor agonist]] (1)

None (1) · 5-HT1A agonist, 5-HT2A antagonist, with weaker activity at D4 and other receptors. Net effect involves enhanced prefrontal dopaminergic/noradrenergic tone with decreased serotonergic inhibition of sexual desire. (1) · '"`UNIQ--vote-000000B6-QINU`"' Active metabolite EXP3174 is ~10-40-fold more potent than the parent and accounts for most of the antihypertensive effect; CYP2C9 polymorphism affects conversion'"`UNIQ--ref-000000B7-QINU`"'. (1) · '"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)

'"`UNIQ--vote-00000063-QINU`"', '"`UNIQ--vote-00000064-QINU`"' (1) · '"`UNIQ--vote-000000B8-QINU`"', '"`UNIQ--vote-000000B9-QINU`"', '"`UNIQ--vote-000000BA-QINU`"', '"`UNIQ--vote-000000BB-QINU`"' (1) · '"`UNIQ--vote-000002C1-QINU`"' (1) · '"`UNIQ--vote-00000764-QINU`"' (1)

100 mg at bedtime daily (1) · 100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) · 50 mg PO daily (25 mg in volume depletion or hepatic impairment) (1) · No current medical indication. Historical anesthetic dose 0.25 mg/kg IV (Sernyl). (1)

100 mg tabs (1) · 25 mg, 50 mg, 100 mg tablets (1) · 25, 50, 100 mg tablets; combination tablets with metformin (1) · Historical: Sernyl 25 mg tablets, 10 mg/mL injection (human); Sernylan 100 mg/mL injection (veterinary). Illicit: white crystalline powder, oily liquid, "dipped" cigarettes ("wet"), tablets. (1)

None · Indication-specific · 40 mg/d · 10 mg/d · 20 mg/d · 80 mg/d · 10 mg/d (adults) · 100 mg/d · 4 g/d · 400 mg/d · 40 mg/d typical; up to 240 mg/d for Zollinger-Ellison · 5 mg/d · 50 mg/d · 600 mg/d · No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals · No fixed maximum; titrated to TSH target · TID per eye · Titrated to glucose; no fixed ceiling · Titrated to glucose; no fixed maximum · '''20 mg/day in adults >60 years''' per FDA's 2011-2012 QT-prolongation warning; 40 mg/day in adults ≤60

Other values:

Search

IM (1) · insufflated (1) · IV (1) · Oral (4) · smoked (1)

BP effect 1-2 weeks; antihypertensive peak 3-6 weeks (1) · Effects accumulate over weeks; assess at 8 weeks (1) · Postprandial glucose effect within days; HbA1c by 12 weeks (1) · Smoked 2-5 min; insufflated 5-15 min; oral 30-60 min; IV / IM ~5-15 min (1)

24 hours (2) · 4-8 hours typical; longer at high doses; residual cognitive and perceptual effects up to 48 hours (1) · Continuous daily dosing (1)

2 hours (parent); 6-9 hours for active carboxylic acid metabolite EXP3174'"`UNIQ--ref-000000BC-QINU`"' (1) · Highly variable, 7-46 hours (mean ~21 h); lipophilic deposition in fat with delayed re-release contributes to wide range'"`UNIQ--ref-00000065-QINU`"' (1) · ~11 h (1) · ~12.4 hours'"`UNIQ--ref-00000765-QINU`"' (1)

~33% (1) · ~33% (extensive first-pass via CYP2C9 and CYP3A4)'"`UNIQ--ref-000000BD-QINU`"' (1) · ~72% oral; ~85% smoked'"`UNIQ--ref-00000066-QINU`"' (1) · ~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1)

None (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-000000BE-QINU`"' (1) · Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not indicated; pregnancy effects unknown (1)

Rx-only in US (REMS program) (1) · [[USLegal:DEA Schedule II|Schedule II]] controlled substance in US (rescheduled from Schedule III in 1978). No accepted medical use. UN Convention on Psychotropic Substances Schedule II internationally.'"`UNIQ--ref-00000067-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US (2)